FrancophonIA/ELRC3.0 huggingface dataset:
English: • Patient-related risk factors include type of F8 gene mutation, severity of haemophilia, ethnicity, family history of inhibitor development and possibly HLA-DR (Human Leukocyte Antigenantigen D Related) constitution.
Slovenian: • dejavniki tveganja, povezani z bolniki, obsegajo vrsto mutacije gena F8, resnost hemofilije, etnično pripadnost, družinsko anamnezo pojava zaviralcev in morda sestavo HLA-DR (humani levkocitni antigen - povezan z antigenom D);
English: However the PRAC is of the view that there are uncertainties with regards to the findings of the SIPPET study which preclude the conclusion that there is a higher risk of inhibitor development in PUPs treated with rFVIII products than pdFVIII products studied in this clinical trial, as detailed below:
Slovenian: Vendar odbor PRAC meni, da obstajajo negotovosti v zvezi z ugotovitvami študije SIPPET, ki preprečujejo zaključek, da obstaja večje tveganje za pojav zaviralcev pri predhodno zdravljenih bolnikih z rFVIII kot s pdFVIII v zdravilih, preučenih v tem kliničnem preskušanju, kot je podrobno opisano v nadaljevanju:
English: T, Mauser-Bunschoten E, Mingot-Castellano ME0, Ozdemir N1, Pabinger I, Parra R1, Pasi J, Peerlinck K, Rauch A6, RousselRobert V, Serban M, Tagliaferri A, Windyga J, Zanon E: Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.
Slovenian: Iorio A, Barbara AM, Makris M, Fischer K, Castaman G, Catarino C, Gilman E, Kavakli K, Lambert T, Lassila R, Lissitchkov T, Mauser-Bunschoten E, Mingot-Castellano ME0, Ozdemir N1, Pabinger I, Parra R1, Pasi J, Peerlinck K, Rauch A6, RousselRobert V, Serban M, Tagliaferri A, Windyga J, Zanon E: Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.
English: Therefore, there is a high degree of uncertainty around extrapolating the SIPPET findings to the entire rFVIII class, particularly for more recently-authorised rFVIII products which were not included in the SIPPET trial.
Slovenian: Zato obstaja velika negotovost glede ekstrapolacije ugotovitev študije SIPPET na celoten razred rFVIII, zlasti za nedavno odobrena zdravila z rFVIII, ki niso bila vključena v preskušanje SIPPET;
English: However, despite the lack of robust evidence to support differential risks between rFVIII products, differential risks cannot be excluded, as this is a heterogeneous product class with differences in composition and formulations.
Slovenian: različnega tveganja med zdravili z rFVIII slednjega ni mogoče izključiti, saj gre za heterogen razred zdravil z razlikami v sestavi in formulacijah.
English: For high-titre inhibitors, the hazard ratio was 1.69 (95% CI, 0.96 to 2.98).
Slovenian: Za zaviralce z visokim titrom je bilo razmerje ogroženosti 1,69 (95-odstotni IZ od 0,96 do 2,98).
English: It found that patients treated with rFVIII products had an 87% higher incidence of all inhibitors than those treated with pdFVIII (which contained VWF) (hazard ratio, 1.87; 95% CI, 1.17 to 2.96).
Slovenian: Ugotovili so, da je pri bolnikih, zdravljenih z zdravili z rFVIII, za 87 % večja pojavnosti vseh zaviralcev kot pri bolnikih, zdravljenih s pdFVIII (ki je vseboval VWF) (razmerje ogroženosti 1,87; 95-odstotni IZ od 1,17 do
English: The CANAL study2 found no evidence of a class difference, including pdFVIII products with considerable quantities of von Willebrand factor; for ‘clinically relevant' inhibitors the adjusted hazard ratio was 0.7 (95% CI 0.4-1.1), and for high titre inhibitors (≥5 BU) was 0.8 (95% CI 0.4-1.3).
Slovenian: V študiji CANAL2 niso našli dokazov o razlikah med razredi, vključno z zdravili s pdFVIII z znatnimi količinami von Willebrandovega faktorja, tako da je bilo za „klinično pomembne“ ravni zaviralcev popravljeno razmerje tveganja 0,7 (95-odstotni IZ 0,4-1,1), za visoke titre zaviralcev (≥ 5 BU) pa 0,8 (95-odstotni IZ 0,4-1,3).
English: Results of clinical studies not sufficiently robust (e.g. suffering from methodolical
Slovenian: Rezultati kliničnih študij, ki niso dovolj robustni (npr. imajo metodološke omejitve), se ne smejo odražati v informacijah o zdravilih s FVIIII.
English: Inhibitors are less likely to occur in previouslytreated patients (PTPs).
Slovenian: Pri predhodno zdravljenih bolnikih (PTP) se zaviralci manj pogosto pojavijo.
English: The SIPPET study was an open-label, randomized, multi-centre, multi-national trial investigating the incidence of neutralising allo-antibodies in patients with severe congenital haemophilia A (plasma FVIII
Slovenian: Študija SIPPET je bila neslepo, randomizirano, multicentrično, večnacionalno preskušanje, v kateri so preučili pojavnost nevtralizirajočih aloprotiteles pri bolnikih s hudo prirojeno hemofilijo A (plazemska koncentracija FVIII < 1 %) s koncentrati pdFVIII ali rFVIII.
English: - http://www.bloodjournal.org/content/121/20/4046.full.pdf
Slovenian: - http://www.bloodjournal.org/content/121/20/4046.full.pdf so iz študije izključili bolnike iz Združenega kraljestva (vključeni tudi v študijo RODIN/Pednet).
English: (another 3rd generation rFVIII) vs Advate, but only for all inhibitor development.
Slovenian: V študiji so odkrili tudi dokaze za povečano tveganje z zdravilom Refacto AF (drugo zdravilo z rFVIII 3. generacije) v primerjavi z zdravilom Advate, vendar le za vse titre zaviralcev.
English: ATC vet code: QI07AJ06.
Slovenian: Oznaka ATC vet: QI07AJ06.
English: Suspension: pink colour with fine sediment.
Slovenian: Suspenzija: rožnato obarvana s finim sedimentom.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/14/163/001
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/14/163/001
English: In case of need, dogs younger than 8 weeks can be vaccinated as safety of this product has been demonstrated in 6 weeks old dogs.
Slovenian: Če je potrebno, lahko cepimo pse, mlajše od 8 tednov, saj je bila varnost tega cepiva dokazana pri psih, starih 6 tednov.
English: Pharmacotherapeutic group: Immunologicals for canidae, live and inactivated viral and inactivated bacterial vaccines.
Slovenian: Farmakoterapevtska skupina: Imunološka zdravila za pse (canidae) - živa in inaktivirana virusna in inaktivirana bakterijska cepiva.
English: MANUFACTURER'S BATCH NUMBER Lot {number}
Slovenian: PROIZVAJALČEVA ŠTEVILKA SERIJE Lot{številka}
English: The duration of immunity against CAV-2 was not established by challenge.
Slovenian: Trajanje imunosti proti CAV-2 ni bilo določeno s preizkusom provokacije.
English: In case of travelling to risk areas or outside the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres ≥ 0.5 IU/ml).
Slovenian: V primeru potovanja na območja z večjim tveganjem ali izven EU se lahko veterinarji odločijo za dodatna cepljenja proti steklini po 12. tednu starosti, da zagotovijo titer protiteles v višini ≥ 0,5 i.e./ml, ki na splošno velja za učinkovito zaščito in obenem izpolnjuje zahteve za potovanje živali (titer protiteles ≥
English: Suspension (inactivated):
Slovenian: Sus pe nzija (inaktivirana):
English: A single dose of Versican Plus DHPPi/L4R should be given every 3 years.
Slovenian: Enkratni odmerek Versican Plus DHPPi/L4R je potrebno dati vsaka 3 leta.
English: Two doses of Versican Plus DHPPi/L4R 3-4 weeks apart from 8-9 weeks of age.
Slovenian: Dva odmerka cepiva Versican Plus DHPPi/L4R v razmaku 3-4 tednov od starosti 8-9 tednov naprej.
English: The vaccine is intended for the active immunisation of healthy puppies and dogs against diseases caused by canine distemper virus, canine parvovirus, canine adenovirus type 1 and 2, canine parainfluenza virus, Leptospira interrogans serogroup Australis serovar Bratislava, Leptospira interrogans serogroup Canicola serovar Canicola, Leptospira kirschneri serogroup Grippotyphosa serovar Grippotyphosa, Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, and rabies virus.
Slovenian: Cepivo je namenjeno aktivni imunizaciji zdravih pasjih mladičev in odraslih psov proti boleznim, ki jih povzročajo virus pasje kuge, pasji parvovirus, pasji adenovirus tipa 1 in 2, virus pasje parainfluence, Leptospira interrogans serološka skupina Australis serovar Bratislava, Leptospira interrogans serološka skupina Canicola serovar Canicola, Leptospira kirschneri serološka skupina Grippotyphosa serovar Grippotyphosa in Leptospira interrogans serološka skupina Icterohaemorrhagiae serovar Icterohaemorrhagiae in virus stekline.
English: At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2, canine parvovirus and rabies.
Slovenian: Vsaj tri leta po osnovnem cepljenju proti virusu pasje kuge, pasjemu adenovirusu tipa 1, pasjemu adenovirusu tipa 2, pasjemu parvovirusu in steklini.
English: Annual re-vaccination is required for Parainfluenza and Leptospira components therefore a single dose of compatible vaccine Versican Plus Pi/L4 can be used annually as required.
Slovenian: Vsako leto je treba ponoviti cepljenje proti virusu parainfluence in komponente Leptospire, za kar se lahko letno uporabi enkratni odmerek kompatibilnega cepiva Versican Plus Pi/L4 na leto kot je potrebno.
English: Name and address of the manufacturer of the biological active substances
Slovenian: Ime in naslov proizvajalca (proizvajalcev) biološke (bioloških) učinkovine (učinkovin):
English: MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Slovenian: PROIZVAJALEC (PROIZVAJALCI) BIOLOŠKE (BIOLOŠKIH) UČINKOVINE (UČINKOVIN) IN PROIZVAJALEC (PROIZVAJALCI) ZDRAVILA, ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJE
English: In this case the second vaccination with Versican Plus DHPPi/L4R should not be given before 12 weeks.
Slovenian: Za prvi odmerek se lahko uporabi cepivo Versican Plus DHPPi/L4, vendar pa v tem primeru cepiva Versican plus DHPPi/L4R za drugo cepljenje ne smete uporabiti pred 12 tednom starosti.
English: Lyophilisate (live attenuated):
Slovenian: Učinkovina(e): Liofilizat (živi atenuirani):
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each dose of 1 ml contains:
Slovenian: Vsak odmerek po (1 ml) vsebuje:
English: PACKAGE LEAFLET: Versican Plus DHPPi/L4R lyophilisate and suspension for suspension for injection for dogs
Slovenian: Versican Plus DHPPi/L4R liofilizat in suspenzija za suspenzijo za injiciranje za pse
English: Name and address of the manufacturer responsible for batch release
Slovenian: ČEŠKA Ime in naslov proizvajalca (proizvajalcev) zdravila, odgovornega (odgovornih) za sproščanje serij
English: ADVICE ON CORRECT ADMINISTRATION Aseptically reconstitute the lyophilisate with suspension.
Slovenian: Odmerjanje in pot uporabe: Aseptično rekonstituirajte liofilizat s suspenzijo.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4R lyophilisate and suspension for suspension for injection for dogs
Slovenian: NAVODILO ZA UPORABO Versican Plus DHPPi/L4R liofilizat in suspenzija za suspenzijo za injiciranje za pse
English: No other adverse effects other than those mentioned under section 6 (Adverse reactions) have been observed after administration of a 10-fold overdose of the vaccine.
Slovenian: 4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno) Po dajanju 10- krat prevelikega odmerka cepiva ni bilo opaziti neželenih učinkov, razen tistih, navedenih v poglavju 4.6.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4R lyophilisate for dogs
Slovenian: Versican Plus DHPPi/L4R liofilizat za pse
English: Suspension (inactivated) : L. interrogans serovar Icterohaemorrhagiae
Slovenian: L. interrogans serovar Icterohaemorrhagiae titer ALR ≥ 1:51
English: Australis serovar Bratislava, - to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, - to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa, and - to prevent mortality, clinical signs and infection caused by rabies virus.
Slovenian: − za preprečevanje kliničnih znakov, izločanja virusa z urinom in zmanjšanje okužb, ki jih povzroča L.interrogans, serološka skupina Canicola,serovar Canicola ter L. interrogans, serološka skupina Icterohaemorrhagiae, serovar Icterohaemorrhagiae,
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus DHPPi/L4R suspension for dogs
Slovenian: Versican Plus DHPPi/L4R suspenzijaza pse
English: Onset of immunity: - 2 weeks after a single vaccination from 12 weeks of age for rabies, - 3 weeks after the first vaccination for CDV, CAV, CPV, - 3 weeks after completion of the primary course for CPiV and - 4 weeks after completion of the primary course for Leptospira components.
Slovenian: − 3 tedne po prvem cepljenju proti CDV, CAV, CPV,
English: Date of latest renewal: 7 January 2019
Slovenian: Datum zadnjega podaljšanja: 7. januar 2019
English: • Information about the risk of hepatic reactions and clinical signs of liver problems
Slovenian: • informacije o tveganju za jetrne reakcije in o kliničnih znakih težav z jetri
English: The Patient's Booklet should contain the following key messages:
Slovenian: Brošura za bolnike mora vsebovati naslednja ključna sporočila:
English: Thymanax should not be used in children and adolescents (under 18 years old).
Slovenian: Zdravilo Thymanax se ne sme uporabljati pri otrocih in mladostnikih (mlajših od 18 let).
English: If you stop taking Thymanax Do not stop taking your medicine without the advice of your doctor even if you feel better.
Slovenian: Če ste prenehali jemati zdravilo Thymanax Ne prenehajte jemati zdravila brez zdravniškega nasveta, niti če se počutite bolje.
English: In healthy volunteers agomelatine preserved sexual function in comparison with paroxetine.
Slovenian: Pri zdravih prostovoljcih se je ob jemanju agomelatin, v primerjavi s paroksetinom, ohranjala spolna funkcija.
English: 9 DATE OF THE FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION Date of first authorisation : 19 February 2009
Slovenian: Datum prve odobritve: 19. februar 2009
English: You must not use Thymanax if your liver does not work properly.
Slovenian: Zdravila Thymanax ne smete jemati, če vaša jetra ne delujejo pravilno.
English: Thymanax should therefore not be used in these patients.
Slovenian: Zdravila Thymanax se zato pri teh bolnikih ne sme uporabljati.
English: The expected benefits of Thymanax are to reduce and gradually remove the symptoms related to your depression.
Slovenian: Pričakovane koristi zdravila Thymanax so zmanjšanje in postopna odprava simptomov, povezanih z depresijo.
English: Bipolar disorder/ mania / hypomania
Slovenian: Bipolarna motnja / manija / hipomanija
English: [EU/1/08/498/002] 14 film-coated tablets [EU/1/08/498/003] 28 film-coated tablets [EU/1/08/498/005] 56 film-coated tablets [EU/1/08/498/006] 84 film-coated tablets [EU/1/08/498/007] 98 film-coated tablets [EU/1/08/498/008] 100 film-coated tablets
Slovenian: [EU/1/08/498/002] 14 filmsko obloženih tablet [EU/1/08/498/003] 28 filmsko obloženih tablet [EU/1/08/498/005] 56 filmsko obloženih tablet [EU/1/08/498/006] 84 filmsko obloženih tablet [EU/1/08/498/007] 98 filmsko obloženih tablet [EU/1/08/498/008] 100 filmsko obloženih tablet
English: A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Thymanax therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Slovenian: Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Thymanax, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
English: There were mild non dose dependent decreases in body weight related to the pharmacological properties and some minor effects on male reproductive tract without any impairment on reproductive performances.
Slovenian: Prišlo je do blagih, od odmerka neodvisnih znižanj telesne mase, povezanih s farmakološkimi lastnostmi, in nekaj manjših učinkov na reproduktivni trakt pri samcih, brez okvare uspešnosti razmnoževanja.
English: The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Thymanax, are provided with patient booklets to be distributed to their patients being prescribed this medicine.
Slovenian: Imetnik dovoljenja za promet z zdravilom bo zagotovil, da bodo vsi zdravniki, ki bodo predvidoma predpisovali ali uporabljali zdravilo Thymanax, prejeli brošure za bolnike, da jih bodo razdelili svojim bolnikom, katerim bodo predpisali to zdravilo.
English: There is no data on the influence of race on agomelatine pharmacokinetics.
Slovenian: Podatkov o vplivu etnične pripadnosti na farmakokinetiko agomelatina ni.
English: Based on the evaluation of these tests your doctor will decide whether you should receive or continue using Thymanax (see also under “How to take Thymanax” in section 3).
Slovenian: Glede na rezultate preiskav se bo zdravnik odločil, ali boste prejeli oz. nadaljevali z jemanjem zdravila Thymanax (glejte tudi poglavje 3 »Kako jemati zdravilo Thymanax«).
English: How to switch from an antidepressant medicine (SSRI/SNRI) to Thymanax?
Slovenian: Kako zamenjati antidepresiv iz skupine SSRI/SNRI z zdravilom Thymanax?
English: - alcohol use disorder and /or substantial alcohol intake and in patients receiving concomitant medicinal products associated with risk of hepatic injury.
Slovenian: - motnja uporabe alkohola in/ali uživanje znatnih količin alkohola, ali pri bolnikih, ki sočasno jemljejo zdravila, ki jih spremlja tveganje za poškodbe jeter.
English: Detailed information on this medicine is available on the European Medicines Agency web site http://www.ema.europa.eu/
Slovenian: Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu.
English: Treatment with Thymanax should only be prescribed after careful consideration of benefit and risk in patients with hepatic injury risk factors e.g.:
Slovenian: Zdravljenje z zdravilom Thymanax lahko predpišete le po skrbnem pretehtanju koristi in tveganja pri bolnikih s prisotnimi dejavniki tveganja za poškodbo jeter, kot so npr.:
English: What Thymanax is and what it is used for What you need to know before you take Thymanax How to take Thymanax
Slovenian: Kaj je zdravilo Thymanax in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Thymanax Kako jemati zdravilo Thymanax
English: 5 How to store Thymanax Contents of the pack and other information
Slovenian: Shranjevanje zdravila Thymanax Vsebina pakiranja in dodatne informacije
English: The Marketing Authorisation Holder shall ensure that at launch and after launch all physicians who are expected to prescribe or use Thymanax are provided with the updated educational material containing the following:
Slovenian: Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bodo ob prihodu na trg in po prihodu na trg vsi zdravniki, ki predpisujejo ali uporabljajo zdravilo Thymanax, prejeli posodobljeno izobraževalno gradivo, ki vsebuje naslednje:
English: As a precautionary measure, it is preferable to avoid the use of Thymanax during pregnancy.
Slovenian: Zaradi previdnosti se je uporabi zdravila Thymanax med nosečnostjo bolje izogniti.
English: Thymanax is used in adults.
Slovenian: Zdravilo Thymanax se uporablja pri odraslih.
English: If Thymanax is initiated while tapering the dosage of the previous medicine, possible discontinuation symptoms should not be confounded with a lack of early effect of Thymanax.
Slovenian: Če vam bodo zdravilo Thymanax uvedli že v času zmanjševanja odmerka prejšnjega zdravila, možnih odtegnitvenih simptomov ne smete zamenjati z odsotnostjo zgodnjega učinka zdravila Thymanax.
English: Thymanax can be taken with or without food.
Slovenian: Zdravilo Thymanax lahko jemljete s hrano ali brez nje.
English: Be vigilant about signs and symptoms that your liver may not be working properly - If you observe any of these signs and symptoms of liver problems: unusual darkening of the urine, light coloured stools, yellow skin/eyes, pain in the upper right belly, unusual fatigue (especially associated with other symptoms listed above), seek urgent advice from a doctor who may advise you to stop taking Thymanax.
Slovenian: Bodite pozorni na znake in simptome, ki kažejo na morebitno nepravilno delovanje vaših jeter - Če opazite katere koli znake in simptome težav z jetri: neobičajno temen urin, svetlo obarvanje blata, rumena koža/oči, bolečina v zgornjem desnem delu trebuha, neobičajna utrujenost (še posebno, če je povezana z drugimi simptomi, navedenimi zgoraj), nujno poiščite pomoč zdravnika, ki vam bo morda svetoval prenehanje zdravljenja z zdravilom Thymanax.
English: Thymanax is not recommended in the treatment of depression in patients under 18 years of age since safety and efficacy of Thymanax have not been established in this age group.
Slovenian: Zdravilo Thymanax ni priporočljivo za zdravljenje depresije pri bolnikih, ki so mlajši od 18 let, ker varnosti in učinkovitosti zdravila Thymanax pri tej starostni skupini niso proučevali.
English: Thymanax film-coated tablets may be taken with or without food.
Slovenian: Filmsko obložene tablete zdravila Thymanax lahko bolniki jemljejo s hrano ali brez nje.
English: If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicineThymanax.
Slovenian: Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
English: During your treatment with Thymanax :
Slovenian: Med zdravljenjem z zdravilom Thymanax:
English: Some patients may get increased levels of liver enzymes in their blood during treatment with Thymanax.
Slovenian: Pri nekaterih bolnikih se lahko vrednosti jetrnih encimov med jemanjem zdravila Thymanax zvišajo.
English: Thymanax starts to act on symptoms of depression in most depressed people within two weeks of starting treatment.
Slovenian: Pri večini bolnikov zdravilo Thymanax začne zmanjševati simptome depresije v dveh tednih po začetku zdravljenja.
English: If you have taken more Thymanax than you should, or if for example a child has taken medicine by accident, contact your doctor immediately.
Slovenian: Če ste vzeli večji odmerek zdravila Thymanax, kot bi smeli Če ste vzeli večji odmerek zdravila Thymanax, kot bi smeli, ali če je na primer zdravilo nehote vzel otrok, takoj obvestite svojega zdravnika.
English: Other medicines and Thymanax
Slovenian: Druga zdravila in zdravilo Thymanax
English: If you forget to take Thymanax
Slovenian: Če ste pozabili vzeti zdravilo Thymanax
English: - If you have increased levels of liver enzymes before treatment, your doctor will decide if Thymanax is right for you.
Slovenian: - Če imate pred zdravljenjem zvišane vrednosti jetrnih encimov, bo vaš zdravnik odločil, ali je zdravilo Thymanax primerno za vas.
English: INFORMATION IN BRAILLE Thymanax 25 mg
Slovenian: PODATKI V BRAILLOVI PISAVI Thymanax 25 mg
English: Thymanax should not be used for the treatment of major depressive episodes in elderly patients with dementia since the safety and efficacy of Thymanax have not been established in these patients.
Slovenian: Uporaba pri starejših z demenco Zdravila Thymanax ne smete predpisovati za zdravljenje velikih depresivnih epizod pri starejših bolnikih z demenco, ker varnosti in učinkovitosti zdravila Thymanax pri tovrstnih bolnikih niso proučevali.